It operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 50% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 19% a year on average.
Sales run at $97.4M a year. A small number, but proof the product has real buyers.
A loss of $91.6M against $97.4M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, FFVWF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FFVWF is a high-risk stock — not yet profitable, and its future rides on its product catching on.